Compare PMN & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMN | TXMD |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 21.3M |
| IPO Year | N/A | N/A |
| Metric | PMN | TXMD |
|---|---|---|
| Price | $8.92 | $1.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $72.67 | N/A |
| AVG Volume (30 Days) | 43.4K | ★ 126.7K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $2,796,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $277.12 |
| Revenue Growth | N/A | ★ 75.19 |
| 52 Week Low | $6.27 | $0.70 |
| 52 Week High | $39.75 | $2.44 |
| Indicator | PMN | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 87.30 | 52.47 |
| Support Level | $7.35 | $1.46 |
| Resistance Level | $9.26 | $2.01 |
| Average True Range (ATR) | 0.64 | 0.17 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 95.98 | 41.38 |
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.